AbbVie's Epkinly Could Be Preferred Frontline DLBCL Agent, UBS Says
MT newswire2026/10/06 16:4112:41 PM EDT, 10/06/2026 (MT Newswires) -- AbbVie's (ABBV) Epkinly could become a preferred frontline option in diffuse large B-cell lymphoma, as its phase 3 result looks favorable against other recently positive regimens on a cross-trial basis, UBS Securities said. The investment firm said in a Monday note that the data would support use of Epkinly with R-CHOP chemotherapy, potentially ahead of combinations such as Roche's Polivy and glofitimab. UBS sees a potential multi-billion-dollar opportunity, versus consensus peak sales of just $1 billion to $2 billion for AbbVie, which splits economics with Genmab. The brokerage also noted the study succeeded in a broader patient population than expected, and said it still needs to see full data and safety, which could come at ASH in December. UBS has a neutral rating on AbbVie, with a $260 price target. Price: 267.95, Change: +2.19, Percent Change: +0.83
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
